Abstract: AIM: To evaluate the therapeutic effect and adverse reactions of combination chemotherapy with NVB and TXT on NSCLC , and to prove the synergistic effect of combination chemotherapy. METHODS: A total of 53 NSCLC patients were randomized into 2 groups, 26 cases of them were treated with NVB at the dose of 25 mg/m² on d 1, d 8, every 21 days. 27 cases of them were treated with NVB at the dose of 25 mg/m² on d1, d8, every 21 days and TXT were administered 75 mg/m² by infusion, with a 3-day pre-medication of corticosteroids b.i.d to reduce the incidence of severe fluid retention and hypersensitivity. RESULTS: NVB group CR, PR, SD, PD, TCR and 1-year survival rate was 0%(0/26), 30.77% (8/26), 53.85%(14/26), 15.38%(4/26), 84.6%(22/26)and 42.31%(11/26). The NVB and TXT group CR, PR, SD, PD, TCR and 1-year survival rate was 3.70%(1/27), 33.33%(9/27), 51.85%(14/27), 11.11%(3/27), 88.9%(24/27) and 51.85% (14/27). There was no statistical significance in the two groups, the common adverse event were bone marrow suppression. There was statistical significance in different two groups (P<0.05). CONCLUSION: Although the effective of combination chemotherapy with NVB and TXT may be a little better than the single NVB,the adverse reactions is more serious.

Key words: NVB, TXT, non-small cell lung cancer